FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan ($19.8 million). Looking up: The…
FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug
The latest: Antengene Corporation Ltd. (6996.HK) announced Friday it has entered into an exclusive collaboration agreement with Hansoh Pharmaceutical Group Co. Ltd. (3692.HK) for the commercialization of the relapse or…
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
